Unraveling the origins of human adeno-associated virus 5

Robert J Gifford, Robert M Kotin

14 June 2023

Commentary

Opportunities to implement continuous processing in production of recombinant adeno-associated viral vectors

G Thakur, S Mink, H Bak et al

06 June 2023

Commentary

Therapeutic mRNA delivery with targeted lipid nanoparticles: next-generation transformative medicines

Umar Iqbal, Jagdeep K Sandhu

27 March 2022

Commentary

Enabling development of commercial-ready lentiviral vector manufacturing processes using stable producer cell lines

Peter Archibald, Ph.D, Anthony Shillings

22 September 2021

Commentary

Making the move from antibody therapeutics to gene therapy: applicability of monoclonal antibody learnings to adeno-associated virus vector bioprocessing

Andrew D Tustian

29 April 2021

Commentary

Considerations for performing virtual quality audits on manufacturers of gene therapy viral vectors: an auditor’s perspective during the COVID-19 public health emergency

Gary C du Moulin, PhD, MPH, RAC

18 March 2021

Commentary

Tools for tomorrow: expression without cells

Jade Tuck, Stuart Jamieson, Philip Probert

08 January 2021

Commentary

Two new capture options for improved purification of large mRNA

P Gagnon, B Goričar, Š Peršič et al

01 September 2020

Commentary

The right analytical toolbox is key to moving your pipeline forward

Andrew Espejo

25 August 2020

Commentary

Analytical Technology Used in the Latest Development of Gene Therapy Candidates

Z Li, Z Wu, T Maekawa et al

16 May 2019

Commentary